Eloxx Pharmaceuticals
Rehovot, Israel· Est.
Ribosome‑targeted small‑molecule platform for rare genetic diseases and cancer.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $15.9M
AI Company Overview
Ribosome‑targeted small‑molecule platform for rare genetic diseases and cancer.
Rare Genetic DiseasesOncology
Technology Platform
TURBO‑ZM™ enables rapid synthesis of low‑molecular‑weight, water‑soluble ribosome‑modulating agents, while RMAs and ERSGs provide selective targeting of eukaryotic ribosomes to promote nonsense‑mutation read‑through or inhibit oncogenic ribosomal mutations.
Opportunities
Successful demonstration of ribosome‑modulating agents could unlock a broad portfolio across rare genetic diseases and oncology, attracting partnership or acquisition interest.
Risk Factors
Technical challenges in achieving selective ribosome modulation, regulatory uncertainty for novel mechanisms, and limited financial runway pose significant execution risks.
Competitive Landscape
Few companies target the ribosome directly; Eloxx differentiates through its TURBO‑ZM™ platform that produces low‑weight, highly soluble oral agents, offering a potential advantage over traditional macrolide and aminoglycoside approaches.